Alameda, CA, June 6, 2006 -- Advanced Cell Technology, Inc. (OTCBB:ACTC) will participate at the European Stem Cells & Regenerative Medicine Congress 2006, June 5-7, at Jumeirah Carlton Tower, London, United Kingdom. Michael D. West, Ph.D., Chairman, President and Chief Scientific Officer, is scheduled to take part in a panel discussion titled Realizing Therapeutic Potential, on Wednesday, June 7th. Dr. West will discuss strategies for the accelerated development of therapeutics from human embryonic stem cells, introduce the Company's ACTCellerate technology platform, and show data on the first new differentiated cells derived using the technology, designated ACTC60.
Human embryonic stem cells (hESC) are the first cells cultured in the laboratory capable of becoming every cell type in the human body. Therefore, the emerging field of regenerative medicine holds great promise for the treatment of many currently untreatable diseases. Despite that potential, researchers have not previously demonstrated efficient means of producing a large array of therapeutically-useful cell types in a pure and scalable form that allows them to be tested for potential human therapeutic use. The Company's proprietary ACTCellerate platform was invented by the Company as a means of accelerating the differentiation of cells from human embryonic stem cells, thereby expanding potential products made from embryonic stem cell technology.
"We are impressed by the ease by which we are able to add new differentiated cells to our pipeline of potential products,” said Michael West. "We believe that our proprietary ACTCellerate technology will allow us to significantly reduce the time required to differentiate important cells that will become target products.” While the embryonic smooth muscle cell line ACTC60 is still very early in the development process, and is still considered only a product candidate, it represents the first of what we believe will be an impressive pipeline of potential new products for a wide array of medical applications.”
"The ACTCellerate technology will generate a solid pipeline of differentiated cells derived from hESC cell lines that are scalable, many of which are cell types not previously isolated,” said William Caldwell, ACT's Chief Executive Officer. "We are excited by the prospect of turning the most promising of these new cell types into marketable products in medicine.”
Dr. West's presentation will be available for viewing at the Company's web site: "www.advancedcell.com/conference-presentations.":http://www.advancedcell.com/conference-presentations
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit "http://www.advancedcell.com":http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Investor Relations: "Vince Daniels":mailto:firstname.lastname@example.org
Media Relations: "Judy Katz":mailto:email@example.com
The Investor Relations Group